RecruitingNot Applicable

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

United States20 participantsStarted 2023-09-08

Plain-language summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Who can participate

Age range30 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 30-85 years * No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer) * Recent diagnosis of MPM * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection Exclusion Criteria: * Aged \<30 or \>85 years at the first outpatient visit * History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

What they're measuring

Change of MPMspecific VOCs

Timeframe: up to 1 year

Trial details

NCT IDNCT06037941

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09

Contact for this trial

Gaetano Rocco, MD

212-639-3478 roccog@mskcc.org

View on ClinicalTrials.gov More Malignant Pleural Mesothelioma trials